Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Baptist Health Herbert Wertheim Cancer Institute Treats Its 100th CAR T-Cell Therapy Patient
Baptist Health Herbert Wertheim Cancer Institute has reached a significant milestone in cancer care: the treatment of its 100th patient with CAR T-cell therapy.
Clinical Scorecard: Baptist Health Herbert Wertheim Cancer Institute Treats Its 100th CAR T-Cell Therapy Patient
At a Glance
Category
Detail
Condition
Certain blood cancers
Key Mechanisms
A patient’s T cells are collected, genetically modified to help detect cancer cells, expanded in a laboratory, and infused after preparatory chemotherapy.
Target Population
Patients with certain blood cancers; the article does not specify eligibility criteria.
Care Setting
The Institute describes onsite cell processing, dedicated inpatient bone marrow and immunotherapy programs, and coordination across evaluation, collection, administration, monitoring, and ongoing care.
Key Highlights
The Institute reports treating its 100th patient with CAR T-cell therapy.
The treatment uses a patient’s own T cells, genetically modified to help the immune system detect and eliminate cancer.
The Institute describes a specially equipped onsite laboratory certified as a Good Manufacturing Practice (GMP) facility.
The Blood and Marrow Stem Cell Transplant Program is accredited by the Foundation for the Accreditation of Cellular Therapy.
Hope Tower at Baptist Health Baptist Hospital houses the Institute’s inpatient bone marrow and immunotherapy programs.
Guideline-Based Recommendations
Diagnosis
The article does not provide diagnostic criteria or a diagnostic workup.
Management
The article describes T-cell collection, genetic modification and laboratory expansion, preparatory chemotherapy, and infusion of the modified cells.
Monitoring & Follow-up
The article mentions monitoring and ongoing care but does not specify protocols.
Risks
The article does not describe treatment risks or adverse effects.
Patient & Prescribing Data
Patients with certain blood cancers considered for CAR T-cell therapy; specific eligibility criteria are not provided.
CAR T-cell therapy uses the patient’s own modified T cells. The article does not provide dosing, product-specific prescribing information, or treatment outcomes.
Clinical Best Practices
The article describes coordination across patient evaluation, cell collection, administration, monitoring, and ongoing care.
The article describes preparatory chemotherapy before infusion of the modified T cells.
The program identifies collaboration among physicians, advanced practice providers, nurses, transplant coordinators, cellular therapy specialists, pharmacists, and clinical and support staff.